OBJECTIVE: Two chronic, traumatic brain injury (TBI) cases, where cognition improved following treatment with red and near-infrared light-emitting diodes (LEDs), applied transcranially to forehead and scalp areas, are presented. BACKGROUND: Significant benefits have been reported following application of transcranial, low-level laser therapy (LLLT) to humans with acute stroke and mice with acute TBI. These are the first case reports documenting improved cognitive function in chronic, TBI patients treated with transcranial LED. METHODS: Treatments were applied bilaterally and to midline sagittal areas using LED cluster heads [2.1″ diameter, 61 diodes (9 × 633 nm, 52 × 870 nm); 12-15 mW per diode; total power: 500 mW; 22.2 mW/cm(2); 13.3 J/cm(2) at scalp (estimated 0.4 J/cm(2) to cortex)]. RESULTS: Seven years after closed-head TBI from a motor vehicle accident, Patient 1 began transcranial LED treatments. Pre-LED, her ability for sustained attention (computer work) lasted 20 min. After eight weekly LED treatments, her sustained attention time increased to 3 h. The patient performs nightly home treatments (5 years); if she stops treating for more than 2 weeks, she regresses. Patient 2 had a history of closed-head trauma (sports/military, and recent fall), and magnetic resonance imaging showed frontoparietal atrophy. Pre-LED, she was on medical disability for 5 months. After 4 months of nightly LED treatments at home, medical disability discontinued; she returned to working full-time as an executive consultant with an international technology consulting firm. Neuropsychological testing after 9 months of transcranial LED indicated significant improvement (+1, +2SD) in executive function (inhibition, inhibition accuracy) and memory, as well as reduction in post-traumatic stress disorder. If she stops treating for more than 1 week, she regresses. At the time of this report, both patients are continuing treatment. CONCLUSIONS: Transcranial LED may improve cognition, reduce costs in TBI treatment, and be applied at home. Controlled studies are warranted.
OBJECTIVE: Two chronic, traumatic brain injury (TBI) cases, where cognition improved following treatment with red and near-infrared light-emitting diodes (LEDs), applied transcranially to forehead and scalp areas, are presented. BACKGROUND: Significant benefits have been reported following application of transcranial, low-level laser therapy (LLLT) to humans with acute stroke and mice with acute TBI. These are the first case reports documenting improved cognitive function in chronic, TBI patients treated with transcranial LED. METHODS: Treatments were applied bilaterally and to midline sagittal areas using LED cluster heads [2.1″ diameter, 61 diodes (9 × 633 nm, 52 × 870 nm); 12-15 mW per diode; total power: 500 mW; 22.2 mW/cm(2); 13.3 J/cm(2) at scalp (estimated 0.4 J/cm(2) to cortex)]. RESULTS: Seven years after closed-head TBI from a motor vehicle accident, Patient 1 began transcranial LED treatments. Pre-LED, her ability for sustained attention (computer work) lasted 20 min. After eight weekly LED treatments, her sustained attention time increased to 3 h. The patient performs nightly home treatments (5 years); if she stops treating for more than 2 weeks, she regresses. Patient 2 had a history of closed-head trauma (sports/military, and recent fall), and magnetic resonance imaging showed frontoparietal atrophy. Pre-LED, she was on medical disability for 5 months. After 4 months of nightly LED treatments at home, medical disability discontinued; she returned to working full-time as an executive consultant with an international technology consulting firm. Neuropsychological testing after 9 months of transcranial LED indicated significant improvement (+1, +2SD) in executive function (inhibition, inhibition accuracy) and memory, as well as reduction in post-traumatic stress disorder. If she stops treating for more than 1 week, she regresses. At the time of this report, both patients are continuing treatment. CONCLUSIONS: Transcranial LED may improve cognition, reduce costs in TBI treatment, and be applied at home. Controlled studies are warranted.
Authors: I K De Scheerder; K Wang; U Kaul; B Singh; H Sahota; M H Keelan; N N Kipshidze; J Moses Journal: Lasers Surg Med Date: 2001 Impact factor: 4.025
Authors: Justin A Zivin; Gregory W Albers; Natan Bornstein; Thomas Chippendale; Bjorn Dahlof; Thomas Devlin; Marc Fisher; Werner Hacke; William Holt; Sanja Ilic; Scott Kasner; Robert Lew; Marshall Nash; Julio Perez; Marilyn Rymer; Peter Schellinger; Dietmar Schneider; Stefan Schwab; Roland Veltkamp; Michael Walker; Jackson Streeter Journal: Stroke Date: 2009-02-20 Impact factor: 7.914
Authors: Gary E Strangman; Therese M O'Neil-Pirozzi; Richard Goldstein; Kalika Kelkar; Douglas I Katz; David Burke; Scott L Rauch; Cary R Savage; Mel B Glenn Journal: Arch Phys Med Rehabil Date: 2008-05 Impact factor: 3.966
Authors: S N Niogi; P Mukherjee; J Ghajar; C Johnson; R A Kolster; R Sarkar; H Lee; M Meeker; R D Zimmerman; G T Manley; B D McCandliss Journal: AJNR Am J Neuroradiol Date: 2008-02-13 Impact factor: 3.825
Authors: R L Mittl; R I Grossman; J F Hiehle; R W Hurst; D R Kauder; T A Gennarelli; G W Alburger Journal: AJNR Am J Neuroradiol Date: 1994-09 Impact factor: 3.825
Authors: Hoon Chung; Tianhong Dai; Sulbha K Sharma; Ying-Ying Huang; James D Carroll; Michael R Hamblin Journal: Ann Biomed Eng Date: 2011-11-02 Impact factor: 3.934
Authors: Sulbha K Sharma; Gitika B Kharkwal; Mari Sajo; Ying-Ying Huang; Luis De Taboada; Thomas McCarthy; Michael R Hamblin Journal: Lasers Surg Med Date: 2011-09 Impact factor: 4.025
Authors: Javad T Hashmi; Ying-Ying Huang; Bushra Z Osmani; Sulbha K Sharma; Margaret A Naeser; Michael R Hamblin Journal: PM R Date: 2010-12 Impact factor: 2.298
Authors: Margaret A Naeser; Ross Zafonte; Maxine H Krengel; Paula I Martin; Judith Frazier; Michael R Hamblin; Jeffrey A Knight; William P Meehan; Errol H Baker Journal: J Neurotrauma Date: 2014-05-08 Impact factor: 5.269